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Abstract
The classical attitude of Nuclear Medicine practitioners on matters of peptide-receptor interactions has maintained
an intrinsic monogamic character since many years. New advances in the field of biochemistry and even in clinical
Nuclear Medicine have challenged this type of thinking, which prompted me to work on this review. The central
issue of this paper will be the use of somatostatin analogs, i.e., octreotide, in clinical imaging procedures as well as
in relation to neuroendocirne tumors. Newly described characteristics of G-protein coupled receptors such as the
formation of receptor mosaics will be discussed. A small section will enumerate the regulatory processes found in
the cell membrane. Possible new interpretations, other than tumor detection, based on imaging procedures with
somatostatin analogs will be presented. The readers will be taken to situations such as inflammation, nociception,
mechanosensing, chemosensing, fibrosis, taste, and vascularity where somatostatin is involved. Thyroid-associated
orbitopathy will be used as a model for the development of multi-agent therapeutics. The final graphical summary
depicts the multifactorial properties of ligand binding.
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The setting
In past issues of the European Journal of Nuclear Medi-
cine and Molecular Imaging, some articles have pointed
out puzzling aspects concerning ligand-receptor interac-
tions. Rolleman et al. have documented the situation of
an apparent positive cooperation between non-labeled
somatostatin (SST) analogs a n dar a d i o - l a b e l e dc o m -
pound in vivo [1]. A similar situation of increased tracer
binding in the presence of 100 μg of cold octreotide had
been shown earlier by Hofland [2]. These data seem to
contradict some views of ligand-receptor interactions
which constitute the basis of the biochemical and
pharmaceutical work that is daily applied in Nuclear
Medicine imaging.
The aim of this short review is to assemble recently
available information on the physiological roles of soma-
tostatin and similar substances, on modern concepts on
receptors, and on binding modulators, in order to
attempt to arrive at a new level of interpretation that
will put a new light on scintigraphic and binding data.
T h e s ed a t as h o u l da l s ob eag u i d i n gc o m p l e m e n tf o r
new peptide tracers being developed [3].
Introduction: the basics of receptor binding and the use
of octreotide
The concepts regarding receptor function have been
accommodated over time to a reductionist model that ide-
ally considers one ligand and one receptor. The basic the-
ories behind were developed between 1900 and 1920
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provided the original work is properly cited.[4-7]. In 1956, the concept of the ability of a drug to
induce an effect after binding-efficacy-was introduced by
Stephenson [8]. This way of thinking fits into the meta-
phor of the “silver bullet”, i.e., a straightforward solution
thought to have outmost effectiveness (or efficacy). Based
on the theories of an allosteric receptor model, Thron dis-
cussed in 1973 the interplay between agonists and antago-
nists [9]. These theorems have found acceptance in the
field of Nuclear Medicine [10] and have been the basis for
experimental and clinical work extending into the modern
field of peptide therapy using SST analogs (SSA) such as
octreotide and lanreotide.
The most known theorem regarding ligand interac-
tions is the Michaelis and Menten reaction [6], defined
as v =( Vmax
.S)/(S + Km). This equation has been
revised recently from the stand point of fractal kinetics
[11] in order to attempt to reach a higher level of
understanding of the biochemical reactions found intra-
cellularly [12]. Aranda et al. state: “Classical enzyme
kinetics, which assumes the Michaelis-Menten paradigm
with perfectly mixed reactants and homogeneous media,
is strongly limited for applications including intracellular
enzyme reactions. A major difference between a diluted
enzymatic system and that found inside the cell is the
high mechanical and rheological complexity of the cyto-
plasmic environment that produces anomalous diffusion
phenomena seriously affecting enzyme kinetics of bio-
chemical pathways” [13]. By a simple process of logical
deduction, we should then expect to have in vivo a
highly complex whole body situation when different
types of tissues are being examined through scintigraphy
with octreotide or other tracers in general.
The basis for the development of SST receptor (SSTR)
imaging can be traced back to the research work done
by Roger Guillemin [14,15]. Somatostatin was first
described in 1973 by Brazeau et al. [16]. The same com-
munication reported the bioactivity of a synthetic repli-
cate. From the industrial point of view, researchers
advanced the development of analogs quite soon after
the discovery of somatostatin. The initial work was
based on peptide chemistry by which the SST sequences
related to peptide binding were identified [17-19]. In
order to validate the binding ability, ligand binding
assays were established [20]. On clinical grounds, one of
the first applications of unlabelled octreotide was the
treatment of acromegaly [21]. In the field of Nuclear
Medicine, radioactive-labeled octreotide tracers have
been in clinical use since the 1990s [22,23] becoming an
established diagnostic procedure [24]. The characteris-
tics of natural and synthetic analogs in relation to recep-
tor internalization, as well as the conformational
changes due to labeling with Yttrium or Gallium have
been recently summarized by Hofland and Lamberts
[25], and by Deshmukh et al. [26], respectively.
It has to be mentioned that some of the in vitro
research with SSA in relation to neuroendocrine tumors
(NET) is based on the use of pancreatic carcinoma cell
lines which had been chemically induced by azaserine
[27]. The histological picture of these tumors varies
from “poorly differentiated solid carcinomas to well-dif-
ferentiated variants which form acini” (rat CA20948
tumors) [27]. Due to the diversity of forms of NET, one
should be cautious when extrapolating results from
these in vitro observations [28]. Unfortunately this cell
line is still in use in 2011.
At the present time, a high level of technological
development has been reached by combining Ga
68-
labeled SST analogs and whole body PET-CT scanning
[29] which now delivers more information about tracer
distribution. In view of this advanced imaging situation
with a higher level of molecular resolution, it is impor-
tant to review the physiology related to SSTR imaging
in order to come to an adequate interpretation.
Somatostatin receptors in fibrosis, vascularity,
inflammation, and taste
Since the 1990s, one main application of SSTR imaging
is in the diagnosis of neuroendocrine tumors [23]. At
the time these tumors are diagnosed, there is usually
clinically evident hepatic involvement. One yet unex-
plained biological characteristic of carcinoids is that to
t e n dt od e v e l o pf i b r o s i s[ 3 0 , 3 1 ] .I ts h o u l db ek e p ti n
mind that liver fibrosis is accompanied by SSTR expres-
sion [32]. The role of stromal fibrosis in connection
with octreotide uptake has been described by Öhrwall et
al. [33]. Lebtahi et al. have shown the influence of pul-
monary tissue fibrosis on octreotide uptake [34]. It fol-
lows that scintigraphic evidence of octreotide uptake
might be an expression of fibrosis, which unfortunately
cannot be distinguished from tumor. In a disease char-
acterized by fibrosis, i.e., fibrous dysplasia, Chen et al.
documented octreotide uptake which remained
unchanged even after treatment with Sandostatin
® [35].
Besides fibrosis, another cause for apparent increase of
binding sites in a tumor might be in relation with blood
vessels [36]. This same property has been praised as a
therapeutical option of somatostatin, i.e., that of being
anti-angiogenic [37,38].
Experimental studies in macaques conducted by Guo
et al. [39] have demonstrated the pattern of physiologi-
cal development and expression of SST in the intestinal
tract. The animals showed expression in mucosal crypts
and as well as in the myenteric nerve plexus. Concomi-
tant to this development the concentration of SST in
the liver declined. Deficiency of SSTR2 can alter the
mesenteric sensitivity of afferent nerves upon distention,
i.e., mechanosensing, or acid exposure, i.e., chemosen-
sing [40]. In addition, SST containing neurons can be
found in the enteric mucosa [41]. Under experimental
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and return to normal after refeeding [42].
Recently Gonkowski and Całka [43] have demon-
strated a modulation of SST immunoreactivity in the
nervous structures of the porcine descending colon
under experimental pathological conditions. In situa-
tions of intestinal inflammation, one can find changes in
the concentration of SST as well as of SSTR [44]. Intest-
inal inflammation can be worsened when SSTR are not
present [45]. In other words, these findings imply that a
functioning SST system seems to be important in the
control of intestinal inflammation [46].
In view of these data, we should ask ourselves: is there
a link between intestinal inflammation and carcinoids?
Recent studies have indeed delivered evidence relating
both processes. West et al. have shown that carcinoids
are 15 times more common in patients with Crohn’s
disease [47]. In a similar way, Grassia et al. have ana-
lyzed the setting of ulcerative colitis [48] and proposed
that long-standing inflammation could induce changes
towards tumor development. Another interesting link
between inflammation and carcinoids has been provided
by Sciola et al. [49]. The authors documented that high
levels of chromogranin A, a marker of neuroendocrine
tumors, can occur in patients with inflammatory bowel
disease. In a more general way, one has to consider the
interactions of the enteric nervous system with the
immune system [50] and situations of intestinal inflam-
mation [51,52]. In an attempt to extrapolate experimen-
tal results, Corleto has recently summarized data that
deals with SSTR knockout mice, which he believes
could be of use for a better understanding of gastroin-
testinal tract functions and SST [53].
Keeping in mind the initial descriptions of SST in the
CNS as well as in GI physiology, it should not surprise
us that SST together with other peptides can be
involved in visceral sensations such as taste [54]. In
addition, homologies between taste receptors and the
sequence of SST and opiate receptors have been
described [55]. The relevance of this homology will be
discussed in the section of heterodimers.
Somatostatin in nociception and its relation to
mechanosensing
A series of studies have documented the relation
between SST and nociception as well as with counter-
regulation in inflammatory situations [56-61]. Changes
in the expression of SSTR can be involved in alterations
of chemical sensitivity as well as of mechanosensing in
afferent mesenteric nerves [62]. Modulation of pain
transmission has a complex circuitry which includes
SSTR [63]. During the sensitization of nociceptors it has
been demonstrated that SST interacts with the vanilloid
receptor TRPV1 [64]. The family of vanilloid receptors
is involved in mechanosensory conduction [65-68]. μ-
Opioid receptor activation can modulate thermal hyper-
sensitivity associated with tissue inflammation through
the TRPV1 channels [69]. It is interesting to note that
in experimental pulp inflammation both SST and opioid
levels are found to be locally increased [70]. While these
actions might seem to be unrelated to SSTR, a later sec-
tion dealing with receptor dimerization will bring more
light into this issue. Taking that SSTR expression is
related to inflammation and nociception in the sur-
roundings of a gastrointestinal tumor, one could expect
that some of tracer binding patterns might be related to
these processes.
Already in 1990, in the article by Lamberts et al. on
the use of iodine-labeled octreotide [71] an anti-noci-
ceptive action of unlabelled short-acting octreotide was
described. In 1991 a similar property was described for
a long-acting somatostatin analog [72]. A newer SSA,
vapreotide, has also been characterized as being anti-
nociceptive [73].
Octreotide scanning in thyroid-associated orbitopathy-what
can we still learn?
In previous studies at the Medical University of
Innsbruck we have been involved in the use of octreo-
tide scanning for the evaluation of the inflammatory
components of thyroid-associated orbitopathy (TAO)
[74,75]. Recently, we have been able to describe muscu-
loskeletal components in this disease based on scinti-
graphic data [76]. While SSTR imaging was positive in
TAO patients, the use of cold Sandostatin
® did not ful-
fill the expectations of clinicians and patients. Based on
the rather disappointing approaches with immune mod-
ulators for the treatment of TAO, we have recently
started to apply a different diagnostic and therapeutic
approach. By applying diagnostic concepts of TCM, one
can characterize these patients as being Qi deficient.
This clinical diagnosis coincides with experimental data
from Liu et al. who used the herbal formulation Sijunzi
(containing Panax ginseng, Poria cocos, Atractylodes
macrocephala,a n dGlycyrrhiza uralensis [77]) in order
to treat experimental Qi deficiency [78]. This treatment
was able to lower the levels of SST in the colon mucosa.
In TAO, we have started to use a multi-agent herbal
preparation based on the use of Western herbs [79].
The formulation used for TAO patients includes Ruta
graveolens [80], Anemone pulsatilla, Hypericum perfora-
tum, Serenoa serrulata, Schisandra chinensis [81],
Ophiopogon japonicus, Glycyrrhiza glabra,a n dZingiber
officinale [79]. Hypericum, first described in 1975 [82],
can affect the sub-cellular localization of the retinoid X
receptor [83] and acts also as antidepressant and anti-
inflammatory [84] also through interaction with the
CRH-1 receptor [85]. Due to interactions of Hypericum
with hepatic metabolism of drugs [86], it is not advisable
to administer it together with other pharmaceuticals.
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preventing inflammation related fibrosis [87]. Serenoa
has been mostly characterized for its use in benign pros-
tate hypertrophy [88]. Schisandra can positively influ-
ence the glutathione levels and thus achieve anti-
oxidative effects [89] while at t h es a m et i m ei tp r o t e c t s
from proteoglycan degradation [90]. The pregnane X
receptor can also be activated both by Schisandra and
Glycyrrhiza [91]. Ophiopogon has anti-inflammatory
properties [92,93]. Finally, Zingiber can inhibit platelet
aggregation and has anti-inflammatory properties
[94-97]. Translating this approach into treatment terms
we can describe it as a multi-agent multi-target strategy.
The reader might ask now, how can this knowledge be
used in Western medicine? Roth and collaborators have
published several articles dealing the investigations of
the receptorome, which is the portion of the proteome
encoding receptors [98]. Based on this principle they
have been able to identify ligands from psychoactive
plants that interact with the receptorome [99]. This is a
multi-agent multi-target environment of real life. Sucher
has recently presented an extensive analysis of herbs for
neuroprotective use which were also investigated under
a multi-component multi-target approach [100]. Straube
et al. have recently proposed the use of multitarget ther-
apeutics for treating headache [101].
While the departing point of this article was to under-
stand the characteristics of scintigraphic studies with
SST analogs, we should be aware that medicinal herbs,
and potentially nutrients also, can interact with peptide
hormones in such a way as to increase the endogenous
levels of SST [102-109]. Similar actions, i.e., raising SST
levels, can also be observed for omeprazole [110], a drug
which is also used in the treatment of carcinoids [111].
Time to think over-somatostatin is not alone-urotensin,
cortistatin, and somatostatin
In 1995, two independent research groups discovered a
new putative neuropeptide receptor called SENR
[55,112]. This was followed by the identification of uro-
tensin as the endogenous ligand for SENR (GPR14)
[113]. Quite recently, an interaction of urotensin II and
of urotensin II-related peptide with SSTR 2 and 5 has
been described [114]. Recent data has also confirmed
the relationship between SSTR genes and those of UII/
URP which are now viewed as a super family [115].
Truncated SSTR have been recently described in
rodents [116]. Neuronostatin, a peptide contained in the
SST gene, has been also described quite recently [117].
New physiological relations can be expected to emerge
for SST and corstistatin due to similar distribution pat-
terns in tumors [118,119]. Another aspect of SST-cortis-
tatin receptors is the association of the cortistatin
MrgX2 receptor to nociception [120,121], thus comple-
menting the functions of SST which were described
above. Cortistatin has not only similarities with the
receptor binding sequence of SST but this also applies
to the SST analogs octreotide and lanreotide [122]. The
initial descriptions of cortistatin were made by de Lecea
et al. [123] followed by Fukusumi et al. [124]
The modern language of receptors: mosaics and dimers,
RAMPS, and arrestins
Our medical and biochemical training has told us that
one correct ligand interacts with one correct receptor.
While it might be correct for in vitro situations where
purified receptors are being used, the biological environ-
ment contains dynamic structures. Early publications on
receptor cooperativity were centered on receptor sys-
tems such as the cardiac muscarinic receptors [125]. In
this setting Wreggett and Welss identified receptor moi-
eties with an apparent molecular mass of 60-75 kDa, as
well as 190 and 240 kDa. These last two species were
interpreted as homotrimers and homotetramers, respec-
tively. In addition the eluted receptors were accompa-
nied by a mixture of guanyl nucleotide-binding proteins
(G-proteins) [125].
The SSTR belongs to the group of G-protein coupled
receptors (GPCR). In GPCR, activation of G proteins is
induced by receptor-effector coupling [126]. In 1998,
Gouldson et al. presented theoretical and experimental
data regarding the hypotheses of receptor dimerization
based on work with the models of the beta2-adrenergic
receptor [127]. They concluded that two processes were
important in GPCR activation namely dimerization and
domain swapping. Non-ligand receptor activation, how-
ever, can also be achieved through receptor-independent
activators of G-protein signaling [128].
Another nomenclature for GPCR is that of the seven-
transmembrane helical receptors (7TM). Several articles
have described characteristics of this family of receptors
[126,129,130]. The five main types of families can be
summarized by the term GRAFS which includes Gluta-
mate, Rhodopsin, Adhesion, Frizzled/taste2, and Secretin
receptors [131,132]. GPCR have the property of forming
dimers, either homo- or heterodimers [133,134]. This
type of association has been also termed receptor
mosaics [135-139]. Keeping these facts in mind, the
reader of this review was already introduced to the con-
cept of fractal analysis of ligand-receptor interactions
[13]. These ideas have been already included in modern
models that look at ligand binding in the “age of
dimers” as we should acknowledge [140,141]. Further
steps in these models are the evaluation of dimer sym-
metry [142] as well as the structural form of these
receptor mosaics which is important for signaling, traf-
ficking, and oligomer intercommunication [143]. Besides
these GPCR models, structural genomics have been
used for protein expression, purification, and crystallo-
graphy [144].
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ing point for new knowledge regarding dimer formation.
Rocheville et al. described the formation of functional
homo- and hetero-dimers [145]. This experiment
unveiled novel biochemical properties of the ligand-
receptor interaction in the sense of molecular cross-talk
among the receptor subtypes. Hukovic et al. have shown
an agonist-dependent regulation of cloned human
SSTR1 [146]. In vivo studies have shown a positive effect
of pre-exposure of SST on the expression of its own
subtype 2 receptors in the arcuate nucleus [147]. In the
following years, more information has been gathered.
Differences in the dimerization of SSTR subtypes have
been investigated by the research groups of Pfeiffer,
Grant, and Jacobs [148-150]. These studies revealed dif-
ferences in receptor kinetics depending on the type of
dimers. Durán-Prado and collaborators have recently
summarized data on heterodimer formation in relation
to SST signaling and control [151]. Besides the situation
of dimerization induced by an agonist, Reubi et al. have
recently described the effect of a DOTA chelator that
changes the action profile of the tracer, i.e., from
antagonist to agonist [152].
While we are accustomed to think exclusively one way
on SST and SSTR while looking at SSTR imaging, real-
life biochemistry might be different. Besides the property
of SSTR dimer formation, heterodimers involving other
receptors types are now known or have been developed
experimentally. One type of heterodimer is related to
dopamine and SSTR which was originally described by
Rocheville [153]. These hetero-oligomers of dopamine
and SSTR had enhanced functional activity. The second
type of heterodimer includes opioid and SSTR, which
were originally described by Pfeiffer et al. [154,155]. In
this context, it is important to mention other work done
on opioid receptors. Using an in vitro system Gomes et
al. [156] have observed that rather low doses of some
delta-selective ligands can lead to a significant increase
in the binding of a mu receptor agonist. It is important
to keep in mind these heterologous interactions since
patients with NET might be treated at some time with
these types of pharmacological agents. Analysis of the
GPRC genome shows interesting relationships of the
SST and opioid receptors [157]. The MCHR2 and
NPBWR2 genes are found at the roots of the SST and
opioid receptors branch. GPR32 and GPR33 are under
the SST and opioid receptor cluster. Among opioid
receptors heterodimers of mu and delta receptors can
be found [156]. A physiological meaning of this type of
heterodimers might be related to nociception.
New data on receptor functioning requires also a new
language. Taking an example of receptor dimerization in
relation to SST [153] Kenakin [158] describes new inter-
actions on the SSTR5-D2 heterodimer, termed conduit,
having SST 14 as a ligand, termed guest. The dopamine
receptor D2 agonist quinpirole increases the binding
affinity of somatostatin-14 while the dopamine receptor
D2 antagonist sulpiride decreases the binding. These
last two are called modulators. O’Toole et al. have
described the co expression of SSTR2 and D2 receptors
in GEP tumors [159]. The authors concluded that bi-
specific agonists such as SST(2)/SST(5) or SST(2)/D(2)
could be tested in these tumors. This type of reasoning
has stimulated research work on the side of the ligands
leading to the synthesis of ligands such as BIM23A357
and BIM23A770 which can bind both SST and dopa-
mine receptors [160]. Recently, Arvigo et al. [161] have
described somatostatin and dopamine receptor interac-
tions in cell lines (prostate and lung cancer). Synergistic
stimulation had effects on the inhibition of cell
proliferation.
Following ligand binding on the cell membrane,
further mechanisms have to control the signaling of the
ligands. One of these mechanisms involves arrestins.
Receptors can be classified according to their ability to
bind arrestin [162]: “Class A receptors (ß2 adrenergic
receptor, mu opioid receptor, endothelin type A recep-
tor, dopamine D1A receptor, and a 1b adrenergic recep-
tor) can bind ß-arrestin2 with higher affinity than ß-
arrestin1 and do not interact with visual arrestin. In
contrast, class B receptors (angiotensin II type 1A recep-
tor, neurotensin receptor 1, vasopressin V2 receptor,
thyrotropin-releasing hormone receptor, and substance
P receptor) bound both ß arrestin isoforms with similar
high affinities and also interacted with visual arrestin”
[162]. The arrestins, ß-1 and ß-2, are negative regulators
of GPCR signaling which translocate to the cell mem-
brane. Here, they bind the occupied receptors. This is
followed by uncoupling of the receptors from G-pro-
teins, leading finally to internalization, and by this,
desensitation occurs [163]. Further actions of arrestin
on histone acetylation and gene transcription have been
described [164]. In a similar way as it happens with
GPCR, the arrestins can also dimerize [165]. SSTR regu-
lation by arrestins has also been demonstrated in recent
years [166-168]. Finally the so-called RAMPS function
as accessory proteins that are needed for the adequate
placing and function of certain GPCRs [169].
GPCR, caveolae, lipid rafts, and oxidative stress
The cellular localization of the receptors implies that
they have to interact with the membrane and this is a
function that depends on its physical properties. I will
mention few structures that are relevant in this context.
The caveolae membrane system describes a functional
complex related to the delivery of molecules to specific
locations in the cell [170]. Subunits of G proteins can
bind to caveolae so that their function is also related to
these elements [171-173]. Finally, the structure of a
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tion of cholesterol can lead to an increase in ligand
binding, however, the level of intracellular signaling
might be reduced [177]. Not only cholesterol (and
maybe cholesterol modifying therapies) but also micro-
n u t r i e n t sc a np l a yar o l eo nm e m b r a n ef l u i d i t y[ 1 7 8 ] .
Membrane rigidity depends also on lipid peroxidation
[179]. Receptor density and membrane fluidity can be
influenced by oxidative stress [180,181]. While oxidative
stress can be sought within the diseased organ, one
should also consider potential side effects of medical
actions. We have recently described the negative influ-
ence of radiation exposure during peptide receptor
radionuclide therapy on Se levels [182]. By decreasing
Se levels, several protective selenoproteins will be com-
promised resulting in impaired protection against oxida-
tive stress [183]. It follows that nutrition, anti-oxidants,
and lipid-modifying therapies have to be included in our
vision of receptor function [184] and possibly modula-
tion. Among the caveolins [185], Caveolin-1 is currently
being investigated in the context of tumor development
[186]. Regulating mechanisms that maintain its expres-
sion could turn to be a potential tumor regulator due to
tumor suppressor functions.
The total environment in the light of PET/CT imaging-
images and postulates
When we carry out SSTR imaging for NET diagnosis,
we are conditioned ap r i o r ito consider octreotide
uptake as tumor expression. We should realize that SST
is only one player among others in a complex system
[187-192]. When we do SSTR imaging, we have to rea-
lize that modern imaging techniques have the potential
of delivering new evidence on the distribution of SSTR.
Based on the use of modern PET/CT imaging with a
Ga
68-labeled octreotide tracer, it is now possible to
detect tracer uptake in bodily structures that have not
been considered before. Figure 1 presents the uptake of
99mTc-labeled HYNIC-TOC in a fibrotic abdominal
surgical scar, showing that tissue repair involves SSTR.
An “ignored” finding in NET patients can be seen in
Figure 2 where tracer uptake within a small intestinal
loop is demonstrated. On theoretical grounds, one can
suspect that an inflammatory process is present. Inflam-
matory gut diseases and NET have been discussed
above.
Figures 3 and 4 depict octreotide localized uptake in
peri-muscular structures of the thigh both in a male and
a female patient. The images have been taken from
PET/CT studies of patients with NET investigated with
68Ga-DOTA-TOC. The distribution pattern delineates
muscular fasciae [193]. For a general description of the
distribution of superficial and deep fasciae of the body,
the readers are referred to Gerlach [194]. Such fascia
structures have a longitudinal distribution between the
muscles and are considered to be involved in epimuscu-
lar myofascial force transmission (e.g., Figure nine in
[195]). Conventional three-view reconstruction algo-
rithms in Nuclear Medicine do not produce a suitable
Figure 1 99mTc
99-HYNIC-TOC uptake in fibrotic scar tissue
after median laparotomy.
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approach to achieve this would be to apply the princi-
ples of diffusion spectrum MRI tractography [196]. The
applicability of this method in the investigation of myo-
cardial, i.e., muscular structures, has been recently
demonstrated [197,198].
Between the fasciae and connective tissue in the body,
tensile forces are active. Standerwick and Roberts have
described these relations for craniofacial growth [199]. I
propose that the punctual uptake is in relation to
mechanosensing, since distension of the muscles, e.g.,
through eccentric exercise, will act on these structures
[200-202]. This is the basic assumption that we have
included in the musculoskeletal model of thyroid-asso-
ciated orbitopathy [76].
The careful observer of figures will also recognize tra-
cer uptake in the subcutaneous fatty structures. While it
is not possible to deliver an exact anatomical correlate
of this binding site, the distribution pattern might be
involved in processes of metabolic signaling such as
lipolysis [203,204]. In humans, changes of both SST
secretion and SSTR expression has been described in
conditions of infection and inflammation of adipose tis-
sue [205].
Recent data on SSTR in the early years of the new century
In the process of editing the final version of this manu-
script, I came across some recent data on SSTR which
should be mentioned here. The data presented above
has in a way a historical character. New developments,
however, change the face of science.
One of the most relevant aspects on SSTR is that of
truncated somatostatin receptors. The group of Cór-
doba-Chacón et al. have described a series of new spli-
cing variants of the SSTR-5 molecule in pituitary
tumors as well as in rodents [206,207]. The result of
these alterations is the appearance of SSTR that have
different numbers of trans-membrane domains (TMD).
In their recent publication [208], they describe some
characteristics of the human spliced variants of the SST
receptor subtype 5. Among these is the novel evidence
that demonstrate that an SST can react in different ways
to very similar analogs of SST. One clinically important
Figure 2 PET/CT Ga
68-TOC uptake in intestinal structures, in abdominal muscles, and abdominal fatty tissue. The image was taken from
a 56-year-old female patient with a NET.
Moncayo EJNMMI Research 2011, 1:9
http://www.ejnmmires.com/content/1/1/9
Page 7 of 16issue is the finding of SST analog-resistant somatotropi-
nomas where the variant called hsst5TMD4 was found
[209]. In their review on the topic of truncated somatos-
tatin receptors, Córdoba-Chacón et al. discuss the issues
that led to a novel reasoning for the interpretation of
SST-knockout models [208]. The data discussed origi-
nated new explanations for the different effects of SST
and cortistatin at different levels. This finding is of out-
most importance in the clinical management of patients
with NET, since sole tracer binding will not be able to
identify the existence of this truncated receptor variant,
while at the same time therapeutic efforts with either
unlabelled or labeled SSTA might remain unsuccessful.
Implementation of these methods in cases of NET is
badly needed!
Besides changes in the receptor peptide structure, a
further factor that influences binding is the carbohydrate
component of the moiety [210]. In a recent article,
Møller et al. discuss the influence of the carbohydrate
component on SSTR (section 2.3.2. in [211]). Glycosyla-
tion moieties are present in SSTR5 [212].
An ample description and discussion on somatostatin
receptors based on the experience with patients with
acromegaly has been recently presented by Colao et al.
[213]. The clear advantage in the field of acromegaly it
that it is possible to investigate the efficacy of different
therapeutic approaches by determining the targets, e.g.,
growth hormone, IGF-I, as well as the characteristics of
the pituitary tumor. This is not always the case in cases
with NET since the decision to initiate treatment might
simply come from scintigraphic results [214] even when
the patients have no significant endocrinological altera-
tions. One important aspect in Colao’s paper is the
description of SSA resistant cases. This situation might
also occur in NET.
Man is not alone in nature. Developmental aspects of
receptors have been presented by other authors. Gahete
et al. have summarized data related to the development
of somatostatin receptors from fish to mammals [215].
E m p h a s i sh a sb e e np u to nt h es e c t i o no nn e wS S T
receptors. In a similar way Vaudry et al. have described
the evolution of urotensin receptors [216]. These early
Figure 3 A 61-year-old male patient presenting intense uptake in muscular structures and in fatty tissues.L o wl e v e l so fS ew e r e
documented in this case.
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accessed for scientific research.
Conclusions: the fiction in science [217,218]
Science is an art. In doing medical research, we attempt
to recognize the elements involved in this art frame and
await confirmation of hypotheses by going through
empirical and evidence-based paths [219-226]. In view
of the biochemical complexity of receptor interaction
outlined in this review, I believe that the most suitable
graphical and operational representation is that of coali-
t i o nc h e s sa sp r o p o s e db yA r n o l dS c h o e n b e r gi nt h e
1920s [227]. Coalition chess involves four players with
each player moving different chess figures. It allows the
possibility to form coalitions between the players-as ago-
nists or antagonists. Using this chess variant as a con-
cept, one can imagine “the players” being involved in
receptor interaction. Modern methods like functional
proteomics and genomics [228], functional nutrige-
nomics [229], receptorome mining [98], chemogenomics
[230], and metabolomics [231] will surely gain relevance
in the field of Nuclear Medicine in order to decipher
these multiple interactions. Multiagent multitarget pro-
cedures, similar to the herbal combination described
herein, could be analyzed by nutriome methods [232].
For NM, one could envision the use of multivalent tra-
cers or tracer mixtures in therapeutic situations. In addi-
tion, we can expect that a new terminology will be
proposed for receptor forms and interactions [233,234].
The influence of morphogens and morphostats on NET
is also added as a research direction to be kept in mind
[190,191,235-240]. Finally, basic research will start to get
involved with spliceosome dynamics [241] in order to
provide answers to the truncated forms of SSTR.
I present a graphical summary of this review in Figure
5. Upon seeing the figure, the reader might recall the
words of William Wordsworth: “My heart leaps up
when I behold a rainbow in the sky”.Ip r o p o s et h a t
when we look at octreotide scintigraphy, while still
strictly sticking to the procedure guidelines [242,243],
we should think on inflammation, nociception, mechan-
o s e n s i n g ,c h e m o s e n s i n g ,f i b r o s i s ,t a s t e ,v a s c u l a r i t y ,a n d
also tumor. An increase of any of these single processes
Figure 4 A 46-year-old female patient with axial mis-alignment, the mid-line is shifted to the left. The uptake intensity is greater as in
the previous case. Axial mis-alignment could influence mechanotension of the muscular structures and produce enhanced SSTR expression.
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rainbow in our imaging sky. While people tend to
believe what they see, and Nuclear Medicine is an ima-
ging specialty indeed, we should not forget the basic
principle of uncertainty in science [244]. Quoting Cas-
tillo while he refers to Feynman [245] one reads: “He
g o e so nt os a yt h a ti fw ea r ef r e eo fd o u b ta n di g n o r -
ance, we will not get any new ideas and make no
progress”.
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